Pfizer Supports the World Cancer Congress and Driving Change in Cancer Care
Pfizer Oncology is proud to be a sponsor of the 2016 World Cancer Congress, the premier forum to unite diverse members of the global cancer community and develop substantial collaborations to drive change for patients globally. This year’s theme, Mobilising Action – Inspiring Change, is one that Pfizer embraces as we strive to redefine life with cancer.
Inspiring Change in Metastatic Breast Cancer
Partnering with the cancer community is vital to improve outcomes and support for cancer patients. In addition to developing cutting-edge treatments, Pfizer cultivates relationships in the cancer community for the collective good, supporting and implementing meaningful programs that positively impact patients around the world. The Union for International Cancer Control (UICC) is an important partner for Pfizer. In 2015, Pfizer and UICC collaborated on a first-of-its-kind initiative, the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC MBC Challenge), awarding $760,000 in grants to 20 organizations in 18 countries to develop mBC-specific projects to address the unique challenges faced by women with mBC around the world.
Programs like the SPARC MBC Challenge are one of the many ways Pfizer collaborates with the breast cancer community to close gaps in patient care and work to improve the outlook for patients. Through our leadership platform, Breast Cancer Vision, Pfizer is addressing the complex challenges of mBC by educating diverse stakeholders to foster better understanding of the gaps that remain; activating them to create global change in care, clinical outcomes, policy and patient support; and innovating around solutions to address unmet needs.
At this year’s Congress, Pfizer is hosting a symposium on “Networks of Care” in mBC as well as the need for psychosocial support and more attention on improving quality of life. The scope of these unmet needs were brought to the forefront in the Global Status of Advanced/Metastatic Breast Cancer 2005-2015 Decade Report, a comprehensive analysis of the global mBC landscape conducted in collaboration with the European School of Oncology. Among the substantial gaps in care, access to resources and support, and treatment outcomes revealed, emotional support and quality of life improvements were the top two patient needs identified in a survey of breast cancer centers commissioned for the report.
Despite some progress, mBC patients continue to struggle with challenges around treatment, support, policy and information, leading them to feel isolated and stigmatized. By shedding light on these challenges, the Global Status of mBC Decade Report and the SPARC MBC Challenge are meant to inspire worldwide change within the cancer community.
WCC occurs every two years, but it is incumbent upon all of us to continually work together as a community to have a meaningful impact on patients’ lives.
As a Bronze sponsor, Institut Curie will present the opening video of the Plenary day1
UICC Newsletter: American Cancer Society Cervical Cancer Symposium and Global Scholars Advocacy Master Course
The American Cancer Society is hosting a master course that will introduce a powerful, proven advocacy training on how to make the change that your constituents need to improve the lives of people in their community. Through a combination of online courses and a full-day in person workshop at the 2016 World Cancer Congress, participants will learn vital components of a successful issue campaign.
Through our partnership with the Young Professionals Chronic Disease Network (YP-CDN) and the NCD Alliance, we will be focusing on youth advocacy and the power of partnerships. Experienced advocates and trainers from the American Cancer Society Cancer Action Network will teach participants about advocacy: what it is, why it works, and how to do it. We will be practicing tenets of Direct Action Organizing (DAO), a well-known practice of grouping like-minded people together to deliver a consistent, thoughtful and deliverable request to those who have the ability to make change. Trainers from YP-CDN and NCD Alliance will focus on many topics, including communication aspects of advocacy, monitoring and evaluating programs, building political accountability for the prevention and control of cancer and other non-communicable diseases, and working to build an effective NCD alliance.
Additionally, the Society is hosting the symposium, Championing the Fight Against Cervical Cancer in the Developing World, which focuses on the high and inequitable burden of cervical cancer. Each year, 266,000 women lose their lives to this disease and approximately 87% of these deaths occur in low- and middle-income countries, according to World Health Organization estimates. Every two minutes a woman dies of cervical cancer around the world, needlessly claiming the lives of our mothers, sisters, wives, and daughters. Today, more women lose their lives to this disease than all complications related to pregnancy and childbirth, and women with HIV are 4 to 5 times more likely to develop cervical cancer than those who are HIV negative. History was made when world leaders chose to recognize cancer and other non-communicable diseases within the 2030 Sustainable Development Goals. The international health and development community must seize on this new window of opportunity to lift the preventable and costly burden of cervical cancer in low- and middle-income countries with an integrated, multisector response.
Focusing on fighting cervical cancer is a priority for the American Cancer Society, not only because it affects so many women, but also because cost-effective and proven prevention, screening, and treatment options exist. To strengthen the case for greater investments in cervical cancer prevention and control, the Society commissioned Harvard University’s T.H. Chan School of Public Health to estimate the economic and health impact of scaling up HPV vaccination and cervical cancer screening coverage for the total target population of women and girls over the next decade in 102 low- and middle-income countries.
Join the American Cancer Society, Cervical Cancer Action and key multisector partners from around the world to learn about new initiatives, campaigns and resources that are supporting a call for increased political commitment and resources to combat the cervical cancer threat that are critically needed in the developing world.
Tuesday, November 1: 9:30am – 11:00am
Cancernomics of Care: Redefining Value in Cancer Management
With rapid developments in health technologies and their related assessment, it is vital that policy decision-makers and cancer control experts are able to assess value holistically when determining access to new medicines and resourcing of the healthcare system. Stakeholders within the wider cancer community play a critical role in shaping the dialogue to help define such value.
To develop the dialogue, key questions need answering such as:
- Who should be consulted in deciding the way in which value is defined in cancer care?
- How and when should their contributions be integrated, and through what process?
To support this discussion, Roche is hosting an interactive satellite symposium on Wednesday 2 November entitled Cancernomics of Care: Redefining Value in Cancer Management. Led by renowned global experts from a range of interested groups, the session will focus specifically on seeking audience input into how stakeholder dialogue should be constructed to help define value in cancer care.
Aligning with the World Cancer Congress 2016 theme of mobilising action and inspiring change, the session aims to engage WCC delegates through an innovative, participatory approach. This methodology involves delegates throughout the duration of the session, continually seeking collective feedback on a set of core policy questions prior to active discussion with the expert panel.
Join us to hear from leading multidisciplinary experts representing both developed and emerging countries as they drive the discussion and participate in a panel debate with patient groups, academia and health policy experts, as well as health economists and anthropologists. To encourage broad thinking on the range of stakeholders that should inform value, the panellists will consider existing research into patient-centred approaches to value (conducted by the Harvard Global Equity Initiative) and the use of QoL assessment tools in the treatment and care of patients (conducted by RAND Europe). Delegates are invited to participate in the dialogue to define tangible outputs that can be used to advocate for appropriate policy outcomes, furthering the debate on value worldwide.
Facilitated by Roche, Cancernomics of Care: Redefining Value in Cancer Management builds on existing partnerships between industry and global cancer stakeholders to continue discussion around this important topic. With increasingly innovative health technologies being developed to tackle previously untreatable diseases, it is essential that the assessment of these medicines evolves so that patients can have access to the medicines that they need.
Symposium sponsor: Roche
Date: Wednesday 2 November
Time: 09:00 – 10:30
Location: Room 351
Building Partnerships to Meet the UN SDG Health Targets:
The Bristol-Myers Squibb Foundation’s Experience
The Bristol-Myers Squibb Foundation has an unwavering commitment to promoting health equity around the globe. Through our grants and partnerships, we are helping many low and middle income countries build capacity to further progress toward prevention and control of cancer and other non-communicable diseases, ultimately helping them to drive progress toward the visionary global goal of reducing deaths from chronic disease 25% by 2025. During the UICC World Cancer Congress in Paris, France, on November 2, our esteemed panel of grantees will reflect on their work on the frontlines of cancer control and how that work supports to the UN Sustainability Development Goals (SDG) for health.
About a decade after the Foundation unveiled its Secure the Future™ initiative to combat HIV/AIDS in Africa, it was discovered that women who survived HIV/AIDS faced another unforeseen health crisis: cervical and breast cancers. Women with HIV are almost five times more likely to develop cervical cancer than women who are HIV negative.
In response, the Foundation joined with a global public-private partnership, Pink Ribbon Red Ribbon (PRRR), to raise awareness and increase access to cervical and breast cancer education, screening and treatment for women in sub-Saharan Africa.
In Tanzania, the cervical cancer rate is 40.6 per 100,000 women, compared to 16 per 100,000 women elsewhere. The Foundation and PRRR are partnering with Medical Women Association of Tanzania (MEWATA), to successfully implement community-based mass screening interventions and engage policy makers to raise awareness and improve access and utilization of breast and cervical cancer screening services.
Viral hepatitis has become an urgent public health concern in Asia. In China, liver cancer is the third leading cause of death; 80% of liver cancers are caused by hepatitis B or C infection. The Foundation has supported hepatitis programs in China since 2002 and works with a range of partners to promote early diagnosis and access to care for viral hepatitis infection to reduce the risk of progression to liver cancer.
Despite overwhelming scientific evidence that links smoking and cancer, tobacco use remains common Central and Eastern Europe (CEE). Tobacco cessation education for healthcare professionals in the region remains minimal, and is non-existent for nurses, who are uniquely positioned to offer cessation assistance to patients given their level of contact throughout a patient’s hospitalization and follow-up visits.
The Foundation partnered with ISNCC to establish a Nursing Center of Excellence in Czech Republic to build nurses’ capacity in evidence-based interventions in tobacco control, to advocate for making tobacco cessation part of national healthcare efforts, and to establish nurse-led tobacco cessation programs in healthcare facilities and communities.
Although cancer remains one of the most common causes of mortality worldwide, there is little awareness of the need for palliative care, and in CEE, most cancer patients die without adequate pain control. The Foundation’s partner in Romania, Hospice Casa Sperantei, is engaging nurses and nurse leaders to expand the reach of palliative care to cancer patients throughout CEE and to integrate palliative care in the formal nursing education system.
Wednesday, November 2: 9:00am – 10:30am
ecancer created a special video for the 2016 WCC
UNICANCER created a special video for the 2016 WCC:
Novartis Oncology is a Proud Sponsor of the UICC-WCC 2016
Open partnerships within the oncology community, as well as with governments, international agencies such as the World Health Organization, foundations and nongovernmental organizations help us achieve a common goal: developing innovative cancer medicines and improving access to treatment.
Novartis Oncology Access
Novartis Oncology Access (NOA) is a sustainable access solution through which Novartis shares the cost of its medicines with government healthcare systems, charities and other payers, or directly with patients without healthcare coverage who are unable to pay for the full cost of their medication. We believe that through this partnership-based approach, we can extend affordable access to a broader number of patients in a sustainable manner.
It is an ongoing mission of Novartis to improve access to medicines within our resources. We have access and donation programs for medicines in many life-threatening diseases, such as malaria, leprosy, and tuberculosis, as well as leukemia and other cancers.
At Novartis Oncology, we are committed to developing innovative cancer medicines and improving access to treatment through our patient assistance and cancer resource programs. We are continually exploring new commercial and access models to best meet the needs of cancer patients and adapt to changing healthcare environments.
Features of the NOA program
NOA offers a unique patient access approach that encompasses different critical features to provide the best patient-centric solutions based on local needs and structure/environment.
- Physician Network –Broader network of physicians and treatment centers so that more patients can connect with, and benefit from, the program.
- Patient Engagement – Patients directly involved and playing an active role in the successful implementation of the program, ensuring greater compliance.
- Tracking System – Global tracking system allows Novartis to provide an uninterrupted flow of medicines to patients in need, as well as to avoid abuse or misappropriation of assets.
NOA in action
NOA is designed to improve access in countries with very limited healthcare reimbursement systems. Today, NOA offers assistance to emerging nations in Asia, the Middle East, Central and Eastern Europe, Africa and Latin America that have challenging healthcare environments.
NOA takes a partnership-based approach through three locally tailored, patient-centric models:
- Shared contribution, in which national or provincial governments and other entities share cost of treatment with Novartis.
- Co-pay, in which the patient shares the cost of treatment with Novartis.
- Full donation of certain products.
The Glivec International Patient Assistance Program
Recognizing from the beginning the critical importance of breakthrough cancer therapy, Novartis Oncology immediately mobilized efforts globally to ensure access to medicines for patients in need. We also developed patient and healthcare professional education and personal support programs that are valuable in maximizing treatment success.
In 2002, Novartis Oncology introduced the Glivec International Patient Assistance Program (GIPAPTM), providing medicines by full donation to properly diagnosed patients in countries around the world without government or private reimbursement and who are unable to pay for the medication.
Access to Medicines – a Solutions-Based Approach (November 3; 09:00 – 10:30; Room 341)
NGO, For-Profit, Government Health Care Provider Perspectives